BDX vs ICUI: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

Reading it: BDX is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. BDX and ICUI share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined BDX and ICUI exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Becton, Dickinson and Company, known as BD, is one of the largest medical technology companies in the world, founded in 1897 and headquartered in Franklin Lakes, New Jersey. Most of what it sells is consumable rather than capital equipment: needles and syringes, IV catheters and vascular access sets, infusion pumps and their disposable sets, surgical and specimen-collection products, prefillable syringes sold to pharmaceutical companies, and interventional devices used in urology, peripheral vascular and surgery. That mix matters because consumables are consumed and reordered, so a large share of revenue recurs each year regardless of hospital capital budgets. Following the February 2026 separation, BD reports in four segments: Medical Essentials (~$1.68 billion in the June 2026 quarter), Interventional (~$1.41 billion), Connected Care (~$1.22 billion) and BioPharma Systems (~$0.67 billion).

Full BDX guide

ICU Medical makes the plumbing of hospital drug delivery. Its Consumables segment sells IV sets, needle-free connectors (the CLAVE family it has built its reputation on), oncology and vascular access products, and tracheostomy devices. Infusion Systems sells the large volume, syringe and ambulatory pumps that push those fluids, including the Plum Duo and Plum Solo platforms plus the LifeShield safety software layer and the CADD and Medfusion pumps inherited from Smiths Medical. Vital Care is the catch-all for temperature management, respiratory, cardiac monitoring and the IV solutions business, most of which now sits inside Otsuka ICU Medical LLC, the joint venture formed in May 2025 when ICU sold 60% of IV Solutions to Otsuka Pharmaceutical Factory America and kept a 40% stake. Revenue for full year 2025 was about $2.23 billion, down roughly 6% on a reported basis almost entirely because of that deconsolidation, with Consumables at about $1.11 billion, Infusion Systems at about $684 million and Vital Care at about $438 million.

Full ICUI guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• BDX drivers: A simpler, pure-play medtech after the Waters separation; BioPharma Systems and injectable drug delivery.
• ICUI drivers: The Infusion Systems replacement cycle; Gross margin recovery.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: The most persistent risk is product liability: BD carries large ongoing litigation over hernia and pelvic mesh and IVC filters, and adverse verdicts or settlement waves can hit cash flow and headlines unpredictably. For ICUI, regulatory and quality exposure is the most specific risk.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick BDX if you believe its drivers more; ICUI if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the BDX and ICUI guides.

BDX. All figures are approximate and tied to the asOf date; check live numbers before acting on any of them. The wide gap between the trailing GAAP multiple (~30x) and the forward multiple (~13x to ~14x) is not a growth forecast, it is mostly an artifact of separation charges, intangible amortization and discontinued-operations accounting depressing reported GAAP earnings, which is why BD and most analysts discuss adjusted EPS. Trailing revenue comparisons across fiscal 2025 and fiscal 2026 are not like-for-like, because the Biosciences and Diagnostic Solutions business moved to discontinued operations after the February 2026 close.

ICUI. At roughly $187 per share, ICUI trades near 21 times the midpoint of its guided adjusted EPS and around 13 times enterprise value to guided adjusted EBITDA, which is a discount to large-cap medical device peers and reflects the leverage plus the unfinished integration. The gap between GAAP and adjusted numbers is unusually wide here, with FY2026 GAAP EPS guided to roughly $1.03 to $1.74 originally and raised to roughly $2.89 to $3.29, because acquisition amortization, restructuring and integration costs are excluded from the adjusted figures. ICU Medical pays no dividend and directs its cash toward debt repayment instead.

Headline figures (approximate, August 2026): BDX shows revenue (ttm, continuing operations) ~$20.8 billion, q3 fiscal 2026 revenue (quarter ended june 2026) ~$5.0 billion, up ~5.4% as reported and ~4.4% currency-neutral, q3 fiscal 2026 eps ~$1.64 GAAP diluted from continuing operations, ~$3.23 adjusted, fiscal 2026 guidance (adjusted diluted eps) ~$12.62 to ~$12.72, with low-single-digit-plus revenue growth; ICUI shows revenue (fy2025) ~$2.23 billion, q2 2026 revenue ~$552 million, ~6% organic growth, adjusted ebitda (fy2026 guide) ~$415 million to ~$435 million, adjusted eps (fy2026 guide) ~$8.60 to ~$9.00.

BDX and ICUI are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined BDX and ICUI exposure against your real portfolio. It is not an investment adviser.